NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases, announced its support for World Hypoparathyroidism Awareness Day by introducing a free Emergency Resources Kit designed to support accurate and more rapid diagnosis of Hypoparathyroidism symptoms in emergency care and other medical care settings. The annual global observance encourages the public to increase awareness of the disorder and the need for more education, improved diagnosis, and new treatment options. NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) net profit margin is -7.10% and weekly performance is 18.86%. On last trading day company shares ended up $31.13. Analysts mean target price for the company is $39.73. NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) distance from 50-day simple moving average (SMA50) is 15.12%.
On May 29, OmniVision Technologies, Inc. (NASDAQ:OVTI) a leading developer of advanced digital imaging solutions, reported financial results for the fourth quarter of fiscal 2014 that ended on April 30, 2014. Revenues for the fourth quarter of fiscal 2014 were $331.0 million, as compared to $352.0 million in the third quarter of fiscal 2014, and $336.2 million in the fourth quarter of fiscal 2013. GAAP net income in the fourth quarter of fiscal 2014 was $15.1 million, or $0.26 per diluted share, as compared to net income of $30.6 million, or $0.54 per diluted share in the third quarter of fiscal 2014, and $8.9 million, or $0.17 per diluted share in the fourth quarter of fiscal 2013. OmniVision Technologies, Inc. (NASDAQ:OVTI) shares advanced 11.62% in last trading session and ended the day on $22.48. Gross Margin is 18.40 % and its return on assets is 7.10 %. OmniVision Technologies, Inc. (NASDAQ:OVTI) quarterly performance is 30.17 %.
Retrophin Inc (NASDAQ:RTRX)‘s stock had its “positive” rating reiterated by ING Group in a research note issued on Friday. Retrophin Inc (NASDAQ:RTRX) shares moved up 13.51% in last trading session and was closed at $14.62, while trading in range of $14.56 – $16.82. Retrophin Inc (NASDAQ:RTRX) year to date (YTD) performance is 108.86%.
Zogenix, Inc. (NASDAQ:ZGNX) a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, announced that Stephen Farr, Ph.D., President, and Ann Rhoads, Chief Financial Officer, will be presenting at the Jefferies 2014 Global Healthcare Conference in New York City on June 4, 2014. Zogenix, Inc. (NASDAQ:ZGNX) ended the last trading day at $2.30. Company weekly volatility is calculated as 7.85% and price to cash ratio as 6.33. Zogenix, Inc. (NASDAQ:ZGNX) showed a positive weekly performance of 14.43%.
On May 19, CytRx Corporation (NASDAQ:CYTR) a biopharmaceutical research and development company specializing in oncology, announced that President and CEO Steven A. Kriegsman and Vice President of Business Development David Haen will present at the Jefferies 2014 Global Healthcare Conference on Wednesday, June 4, 2014 at 9:30 a.m. Eastern Time. The conference is being held June 2-5 in New York City. CytRx Corporation (NASDAQ:CYTR) weekly performance is 15.47%. On last trading day company shares ended up $4.18. Analysts mean target price for the company is $11.00. CytRx Corporation (NASDAQ:CYTR) distance from 50-day simple moving average (SMA50) is 22.11%.